Catalyst Calendar
Scope

Mon, Jun 22, 2026

1 updates
ARWR
12:33 PM

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the condition People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing

arrowheadpharma.com

Thu, Jun 18, 2026

1 updates

Tue, Jun 2, 2026

1 updates
ARWR
7:30 AM

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

PASADENA, Calif. --(BUSINESS WIRE)--Jun. 2, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2026 Jefferies Global Healthcare Conference – June 2-4, 2026 Type: Fireside Chat Presentation Date/Time: June 3,

arrowheadpharma.com

Wed, May 27, 2026

1 updates
ARWR
7:00 AM

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

- Targeting Activin E may represent a novel therapeutic strategy for metabolic dysfunction-associated steatohepatitis (MASH) and obesity‑related metabolic dysfunction - ARO-INHBE produced meaningful reductions in liver fat content as a monotherapy or in combination with low-dose tirzepatide in

Presentation / Abstract • Phase 1/2EASL 2026 poster presentation Wed, May 27, 2026arrowheadpharma.com

Tue, May 26, 2026

1 updates
ARWR
10:00 AM

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress

- New data support potential use of plozasiran without dose adjustment in patients with moderate-to-severe renal or moderate hepatic impairment - Case report suggests that preconception exposure to plozasiran may be associated with sustained lowering of fasting triglyceride levels throughout the

Presentation / Abstract • Phase 3Oral presentation Tue, May 26, 2026, 8:30 AM EESTarrowheadpharma.com

Thu, May 7, 2026

1 updates

Tue, May 5, 2026

1 updates

Mon, May 4, 2026

1 updates
ARWR
7:30 AM

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

PASADENA, Calif. --(BUSINESS WIRE)--May 4, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: BofA Securities 2026 Healthcare Conference – May 12-14, 2026 Type: Investor Group Dinner Date/Time: May 12, 2026

Presentation / Abstractarrowheadpharma.com

Fri, May 1, 2026

1 updates

Fri, Apr 24, 2026

1 updates
ARWR
6:39 AM

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe

– If confirmed by the European Commission, REDEMPLO would be the first and only siRNA medicine authorized in the EU for both genetically confirmed and clinically diagnosed adult patients with FCS – People living with FCS have extremely high triglyceride levels and a substantially higher risk of

arrowheadpharma.com

Mon, Apr 20, 2026

1 updates
ARWR
4:01 PM

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results

PASADENA, Calif. --(BUSINESS WIRE)--Apr. 20, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 7, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 second quarter ended March 31, 2026.

arrowheadpharma.com